ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc (ZNTL)

2.44
0.02
( 0.83% )
Actualizado: 12:04:52

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
2.44
Postura de Compra
2.44
Postura de Venta
2.45
Volume Operado de la Acción
365,006
2.4001 Rango del Día 2.58
1.61 Rango de 52 semanas 18.07
Capitalización de Mercado [m]
Precio Anterior
2.42
Precio de Apertura
2.43
Última hora de negociación
12:09:22
Volumen financiero
US$ 913,033
Precio Promedio Ponderado
2.5014
Volumen promedio (3 m)
1,912,938
Acciones en circulación
71,265,400
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.60
Beneficio por acción (BPA)
-4.1
turnover
-
Beneficio neto
-292.19M

Acerca de Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets a... Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Zentalis Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZNTL. The last closing price for Zentalis Pharmaceuticals was US$2.42. Over the last year, Zentalis Pharmaceuticals shares have traded in a share price range of US$ 1.61 to US$ 18.07.

Zentalis Pharmaceuticals currently has 71,265,400 shares in issue. The market capitalisation of Zentalis Pharmaceuticals is US$172.46 million. Zentalis Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.60.

ZNTL Últimas noticias

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.442222.581.950711552962.27645844CS
40.187.964601769912.262.581.6130457082.0475435CS
12-1.03-29.68299711823.4741.6119129382.47838476CS
26-0.64-20.77922077923.085.441.6118907493.07614238CS
52-10.53-81.187355435612.9718.071.6115055284.99718339CS
156-46.73-95.037624567849.1752.851.6199121213.71374336CS
260-22.25-90.117456460124.6987.191.6170796319.35321814CS

ZNTL - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Zentalis Pharmaceuticals?
El precio actual de las acciones de Zentalis Pharmaceuticals es US$ 2.44
¿Cuántas acciones de Zentalis Pharmaceuticals están en circulación?
Zentalis Pharmaceuticals tiene 71,265,400 acciones en circulación
¿Cuál es la capitalización de mercado de Zentalis Pharmaceuticals?
La capitalización de mercado de Zentalis Pharmaceuticals es USD 172.46M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals ha negociado en un rango de US$ 1.61 a US$ 18.07 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Zentalis Pharmaceuticals?
El ratio precio/beneficio de Zentalis Pharmaceuticals es -0.6
¿Cuál es la moneda de reporte de Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Zentalis Pharmaceuticals?
El último beneficio anual de Zentalis Pharmaceuticals es USD -292.19M
¿Cuál es la dirección registrada de Zentalis Pharmaceuticals?
La dirección registrada de Zentalis Pharmaceuticals es CORPORATION TRUST CENTER, 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Zentalis Pharmaceuticals?
La dirección del sitio web de Zentalis Pharmaceuticals es www.zentalis.com
¿En qué sector industrial opera Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
STAIScanTech AI Systems Inc
US$ 3.8803
(89.28%)
111.4M
KWEKWESST Micro Systems Inc
US$ 0.7916
(69.51%)
215.19M
EFOIEnergy Focus Inc
US$ 1.90
(47.29%)
35.12M
PRPHProPhase Labs Inc
US$ 0.4784
(47.20%)
162.43M
DATSDatChat Inc
US$ 3.7064
(44.78%)
3.37M
INLFINLIF Limited
US$ 3.07
(-81.20%)
6.53M
BPTHBio Path Holdings Inc
US$ 0.212001
(-66.52%)
4.86M
SEPNSepterna Inc
US$ 4.83
(-62.73%)
4.77M
PTPIPetros Pharmaceuticals Inc
US$ 0.1382
(-52.83%)
21.6M
RSLSReShape Lifesciences Inc
US$ 1.125
(-51.72%)
4.55M
ADTXAditxt Inc
US$ 0.10
(42.86%)
480.54M
KWEKWESST Micro Systems Inc
US$ 0.7914
(69.46%)
215.4M
PRPHProPhase Labs Inc
US$ 0.4784
(47.20%)
162.91M
INTCIntel Corporation
US$ 26.0699
(10.47%)
127.08M
STAIScanTech AI Systems Inc
US$ 3.875
(89.02%)
111.6M

ZNTL Discussion

Ver más
glenn1919 glenn1919 3 días hace
ZNTL.......................................https://stockcharts.com/h-sc/ui?s=ZNTL&p=W&b=5&g=0&id=p86431144783
👍️0
glenn1919 glenn1919 2 semanas hace
ZNTL......................https://stockcharts.com/h-sc/ui?s=ZNTL&p=W&b=5&g=0&id=p86431144783
👍️0
dcaf7 dcaf7 2 semanas hace
Three insiders including CEO bought ZNTL shares.
👍️0
dcaf7 dcaf7 3 semanas hace
Is it a buying opportunity? Looks like a lot of uncertainty removed.
👍️0
Awl416 Awl416 5 meses hace
Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
👍️0
glenn1919 glenn1919 5 meses hace
ZNTL.......................................https://stockcharts.com/h-sc/ui?s=ZNTL&p=W&b=5&g=0&id=p86431144783
👍️0
Monksdream Monksdream 6 meses hace
ZNTL under $4
👍️0
ANTADOG ANTADOG 5 años hace
We managed to get a new 26 week high and a reset around 46 bucks, will be interesting to see where it goes next, chartwise it's up, imo of course, ANT
👍️0
ANTADOG ANTADOG 5 años hace
Added some 46's , nice chart reset, ANT
👍️0
ANTADOG ANTADOG 5 años hace
55.12~~ looks like this puppy is on it's way for a new 52 week high, my target here is 100 bucks because of the very promising pipeline , fyi imo ANT
👍️0
ANTADOG ANTADOG 5 años hace
NEW YORK and SAN DIEGO, June 15, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that Ahmed Samatar, Ph.D., Senior Vice President of Oncology Research at Zentalis, will present preclinical data on ZN-c5 at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting II taking place June 22-24th.

The preclinical data demonstrated that ZN-c5, the Company’s oral selective estrogen receptor degrader (SERD) product candidate, had antitumor activity in human tumor breast cancer xenograft models. ZN-c5 also displayed excellent oral bioavailability across several preclinical species. ZN-c5 is currently being evaluated in a Phase 1/2 clinical trial in patients with ER+/HER2- advanced or metastatic breast cancer both as a single agent and in combination studies.
👍️0
ANTADOG ANTADOG 5 años hace
NEW YORK and SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals (ZNTL), a clinical-stage biopharmaceutical company focused on developing clinically differentiated, novel small molecule therapeutics that target fundamental pathways of cancers, today announced that Anthony Sun, MD, Chairman and Chief Executive Officer of Zentalis, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 1:30 p.m. ET.
fyi ANT
👍️0
ANTADOG ANTADOG 5 años hace
New 52 week high at 52.09, i luv it, ANT
👍️0
ANTADOG ANTADOG 5 años hace
Cash Position: As of March 31, 2020, Zentalis had cash and cash equivalents of $63.7 million. We expect that the Company’s existing cash and cash equivalents, together with the net proceeds of $172.4 million from the IPO, will enable the Company to fund its operating expenses and capital expenditure requirements into 2022.
fyi ANT
👍️0
ANTADOG ANTADOG 5 años hace
Chart is pretty fresh here, anyway, i see a trendline curlin' up already (10ma on the daily at 35.9), fyi ANT
👍️0
ANTADOG ANTADOG 5 años hace
promisin' co, interestin' pipeline, touched new 52 week high today (42.83), enormous spread every now and then, fyi ANT
👍️0
crudeoil24 crudeoil24 5 años hace
ZNTL opens @ 25.20 >
👍️0
crudeoil24 crudeoil24 5 años hace
Zentalis Pharma Upsized IPO Prices at High End of Range >ZNTL
6:08 am ET April 3, 2020 (Dow Jones) Print
By Colin Kellaher

Zentalis Pharmaceuticals Inc. said its upsized initial public offering of 9.18 million shares was priced at $18 each, the high end of the expected range.

The New York clinical-stage cancer biopharmaceutical company earlier this week said it expected to sell 7.65 million shares at $16 to $18 apiece.

Zentalis said it expects gross proceeds of $165.2 million from the IPO, adding that it has granted the underwriters an option to buy up to 1.38 million additional shares.

Zentalis previously said it will use proceeds from the offering to advance the development of its drug candidates.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 03, 2020 06:08 ET (10:08 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
👍️0
crudeoil24 crudeoil24 5 años hace
Zentalis Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative. Its other products include ZN-c3, an oral and small molecule inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
👍️0